PITTSBURGH (PRWEB)
December 18, 2019

Consegna Pharma Inc. today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), valued at approximately $218,000 for the continued development of CP216, the company’s sustained-release naloxone formulation for the reversal of opioid overdoses. The award is being made under NIH’s HEAL (Helping to End Addiction Long-termSM) Initiative that was launched in 2018 to improve prevention and treatment strategies for opioid misuse and addiction and enhance pain management. Consegna’s award is one of 375 grant awards across 41 states made by the NIH in fiscal year 2019 to apply scientific solutions to reverse the national opioid crisis.

70,237 drug overdose deaths occurred in the United States in 2017. Opioids—mainly synthetic opioids such as fentanyl—are currently the primary driver of drug overdose deaths. While naloxone has proven invaluable as an opioid overdose antidote, naloxone suffers from a very short duration of action (about 1hr.) and has been found to be less effective against newer, long acting synthetic opioids including fentanyl (about 7-10 hrs.). This leads to a highly lethal and increasingly prevalent phenomenon known as “renarcotization”, wherein an overdose patient revived with naloxone can re-enter an overdose state due to residual fentanyl in the body.

“We are pleased to be among the organizations selected to receive a Phase I award,” said Larry Zana, President and CEO. “Consegna has dedicated itself to the mission of addressing the opioid crisis with novel polymer-based formulations. We believe that CP216 has the potential to save lives by reducing the incidence of renarcotization.”

CP216 is a novel microparticle formulation that provides an immediate release of naloxone to reverse an overdose, followed by a continuous release of naloxone over the next 24hrs to prevent renarcotization. This Phase I STTR award will enable Consegna to conduct non-clinical studies and activities to demonstrate proof-of-concept for CP216.

“It’s clear that a multi-pronged scientific approach is needed to reduce the risks of opioids, accelerate development of effective non-opioid therapies for pain and provide more flexible and effective options for treating addiction to opioids,” said NIH Director Francis S. Collins, M.D., Ph.D., who launched the initiative in early 2018. “This unprecedented investment in the NIH HEAL Initiative demonstrates the commitment to reversing this devastating crisis.”

This grant award is supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R41DA050386. The content of this press release is solely the responsibility of the company and does not necessarily represent the official views of the National Institutes of Health.

About the NIH HEAL Initiative: The National Institutes of Health launched the HEAL (Helping to End Addiction Long-termSM) Initiative in April 2018 to improve prevention and treatment strategies for opioid misuse and addiction and enhance pain management. The NIH HEAL Initiative aims to improve treatments for chronic pain, curb the rates of opioid use disorder and overdose and facilitate long-term recovery from opioid addiction.

# # #

About Consegna Pharma: Consegna Pharma reformulates FDA approved drug products and creates new, long-acting injectable (LAI) medications with improved clinical and economic benefits. Consegna’s product pipeline focuses on therapeutic areas where LAIs offer high therapeutic and economic value, such as addressing high non-adherence, improving efficacy, reducing side effects, or solving specific drug delivery challenges. The company uses its artificial intelligence-based Computational Drug Delivery™ technology, called ADSR™, to design LAIs significantly faster than legacy practice and with reduced clinical and technical risk.

Share article on social media or email:

CARLSBAD, Calif. (PRWEB)
December 17, 2019

LabArchives, the leading digital lab notebook for course instruction, released a molecular biology course pack within the LabArchives learning platform. The course pack also includes access to SnapGene, the leading molecular biology software solution.

The molecular biology course pack is an all-in-one package for instructors to use in relevant courses. The course pack comes with access to LabArchives, molecular biology software SnapGene and content designed for course instruction. While this first course pack release is designed for molecular biology, LabArchives has prepared similar ready-made content for a variety of subjects.

This molecular biology course pack includes two modules containing 19 labs and supporting materials (prep sheets, instructor support materials and more). The pack delivers two different semester-long projects that utilize key molecular biology techniques and computational tools. Instructors can pick and customize content from the course pack to align with teaching objectives and available equipment.

For students, this content provides an authentic learning experience. This course pack utilizes tools and technology used in professional research labs. The LabArchives ELN and SnapGene can be found in many ‘real world’ molecular biology labs. Students will also learn to direct their own inquiry, a valuable skill as they move forward in any lab setting.

LabArchives will expand content offerings in other major disciplines. A third module to the molecular biology course pack is in process and additional labs and instructor resources will be added soon.

About SnapGene

SnapGene was founded by scientists and software designers to meet the everyday needs of molecular biologists. SnapGene desktop software (snapgene.com) is used in more than 65 countries, in virtually every major research institution, and in most of the largest pharmaceutical and biotech companies worldwide. The software provides a simple yet powerful way for researchers to plan, visualize, document, and share their everyday molecular biology procedures. Free trials of the software are available from the SnapGene website. SnapGene is an Insightful Science product.

About LabArchives:

LabArchives is a SaaS application platform used in research labs and higher education laboratory courses. LabArchives products are used by more than 400,000 scientists and professors to store, organize, share and publish their laboratory data. The LabArchives Classroom Edition has been used in 7,200 lab courses by 270,000 students. More than 400 of the world’s leading research institutions trust LabArchives for research data management, collection and research compliance. For more information, visit https://blog.labarchives.com/, https://www.labarchives.com or see us on Facebook, Twitter and LinkedIn.

Share article on social media or email:

GoMarketing Healthcare Medical Online Marketing Division

Our Healthcare Clients have benefited greatly in the past 10 years with our marketing programs. Dedicating a team to this vibrant industry is an evolution of our services – Richard Uzelac, CEO GoMarketing Inc.

THOUSAND OAKS, Calif. (PRWEB)
December 16, 2019

In preparation for 2020, GoMarketing has launched a division dedicated to servicing and communicating their digital marketing solutions for the healthcare and medical industry. The new digital collateral on GoMarketing.com breaks down the types of medical entities that can benefit from digital marketing and advertising, as well as more detailed information about their services tailored to healthcare professionals.

“Under this industry-specific initiative, GoMarketing now accommodates businesses and clinics that serve the following specialties in modern medicine: skilled nursing, mental health, home health and hospice, outpatient therapy, physical therapy, diet and nutrition, and more,” said Richard Uzelac, CEO of GoMarketing Inc.

With more and more potential patients searching for medical specialists online, it is more important than ever for clinics and practices to not just be visible, but also available via digital devices. Websites for healthcare entities ought to be integrated with the latest tools such as live chat, intake forms, and appointment scheduling to accommodate patient needs and demands. “As the medical industry continues to innovate and go digital, GoMarketing is excited to provide web development tools and digital marketing services that clinics and facilities need to stay cutting-edge in 2020 and beyond,” says Richard Uzelac, CEO and founder of GoMarketing.

In addition to offering premium digital assets and solutions for the healthcare sector, GoMarketing is a versatile, full-service marketing and advertising agency for home service companies, real estate professionals and brokerages, local small businesses, and more. Their valued clients span Southern California throughout Ventura and Los Angeles County. To learn more about their digital marketing services targeted towards medical professionals and clinics, visit:

https://gomarketing.com/industries/healthcare-marketing-agency/

About GoMarketing

Based out of Thousand Oaks, California, GoMarketing. uses the following mission statement to deliver digital marketing results to their clients: “Understand. Engage. Succeed. Grow.” Acting as digital marketing professionals within a wide range of industry sectors, the GoMarketing team specializes in SEO, content strategy, website design and development, and more–providing a full suite of marketing solutions that generate online leads and sales for businesses throughout Southern California. For more information about their custom marketing plans, contact Richard Uzelac, CEO of GoMarketing directly at 805.413.7893 or visit http://www.gomarketing.com.

About Richard Uzelac

Founder of GoMarketing and RealtyTech Inc., Richard Uzelac is an Emmy award-winning graphics producer, former Director of Realtor.com, and sits on several boards of directors. Richard Uzelac’s GoMarketing works with Corporations and Small Businesses to generate exposure, sales and improve online reputation. Mr. Richard Uzelac is also available as a Technology Speaker, Seminar Provider and Business Consultant. For more information, contact Richard Uzelac at 805.413.7893.

Share article on social media or email:

BEAVERTON, Ore. (PRWEB)
December 12, 2019

ZRT Laboratory is pleased to announce the launch of a new LCMS Saliva Steroid Profile to be added to the existing suite of saliva test offerings. While ZRT’s salivary hormone immunoassays continue to provide highly accurate results, there are some analytes that cannot be tested using this methodology because there are no available immunoassays. ZRT has therefore developed an assay using liquid chromatography/tandem mass spectrometry (LC-MS/MS, or LCMS). This profile tests a broad range of bioidentical hormones, ethinyl estradiol, and several synthetic hormone synthesis inhibitors, which are all reported together from one convenient saliva sample collection.

David Zava PhD, ZRT’s Founder and Chief Scientist, explains, “While dried urine testing for steroid metabolites shows the end result of hormone metabolism – the ‘garbage dump’ of inactive hormones – the new LCMS Saliva Steroid Profile shows the bioavailable levels of active hormones and hormone synthesis inhibitors that are currently circulating around the body and acting at hormone receptors or hormone synthesis enzymes, giving a clear window into how they are affecting health.”

The addition of this new LCMS Profile gives ZRT the distinction of being the first and only lab to offer providers a test for ethinyl estradiol, the most common component of oral contraceptives. Testing ethinyl estradiol along with the other estrogens in the profile helps providers assess the total body burden of estrogens on their patients using most oral birth control formulations, and thereby assess symptoms in the light of their overall hormone picture. LCMS testing also allows for accurate reporting of hormones often present and active at very low levels, such as estrogens and androgens seen in men, children, postmenopausal women, and people using aromatase and 5a-reductase inhibitors of hormone synthesis.

ZRT’s LCMS saliva steroid profile also gives providers a comprehensive range of androgen tests that can be used for a full assessment of women with hair loss or acne. Saliva melatonin was also added to this new profile to give providers an assessment of real-time waking melatonin production and help identify possible sleep problems. Finally, to complete the hormone picture, ZRT includes the hormone blockers anastrozole, letrozole and finasteride to evaluate the effects of these drugs on steroid hormone metabolism in terms of buildup or deficiency of key hormones, as well as treatment compliance.

To learn more about ZRT’s new LCMS Saliva Steroid Profile or to order yours today, visit ZRT’s saliva page or contact customer service at 866.600.1636 or email info@zrtlab.com.

About ZRT Laboratory

ZRT Laboratory is a CLIA-certified commercial and research laboratory founded in 1998 by breast cancer researcher David Zava, Ph.D. ZRT has pioneered innovative testing methods for hormones, neurotransmitters, heavy metals and more, offering health care professionals convenient and simple at home options for collection of different body fluids including saliva, dried blood spot, and dried urine. With over 10 million clinical tests performed over the past 20+ years, coupled with our signature personalized test report, ZRT Laboratory has become a world recognized leader in hormone and wellness testing. Individuals, health care providers in all 50 states and in over 100 countries, as well as research-oriented government, private, and academic organizations worldwide use our testing. Learn more at zrtlab.com.

Share article on social media or email:

LAS VEGAS (PRWEB)
December 11, 2019

Sovereign Laboratories, a worldwide leader in the bovine colostrum supplement industry, will host a booth (#3078) at the 27th annual A4M World Congress held in Las Vegas, Nevada, from December 13-15, 2019. Along with a booth, Drs. Mark Tager, M.D., Michele Neil-Sherwood, D.O., and Mark Sherwood, N.D., will present a panel discussion on the topic of incorporating bovine colostrum into a healthcare practice at the A4M Product Theater.

Titled “Introducing Bovine Colostrum to Your Patients: From the Practitioner’s Perspective,” the panel will be held on Friday, December 13, from 1:00 to 1:30pm. Dr. Tager, who serves as medical marketing consultant for Sovereign Laboratories, will act as moderator of the discussion panel. Drs. Michele Neil-Sherwood and Mark Sherwood operate the Functional Medical Institute, a private practice based in Tulsa, OK, that focuses on integrated, holistic approaches to health.

“We are excited to return to A4M this year as an opportunity to further learn and grow,” says Douglas Wyatt, founder of Sovereign Laboratories, “The A4M Conference gives us a chance to connect with thousands of medical professionals from all over the world, allowing us to spread the good word about the benefits of bovine colostrum supplements in gut health and beyond. We are especially excited for Dr. Tager’s talk with Drs. Michele and Mark and hope it will provide medical practitioners with greater insight into providing patients with bovine colostrum.”

Dr. Tager has served as a consultant in the fields of natural products, regenerative medicine, laboratory sciences, and aesthetics, and he has conducted over 1,000 presentations and written nine books. Drs. Neil-Sherwood and Sherwood have co-written two Amazon bestselling books, Fork Your Diet and The Quest for Wellness, and have cultivated a YouTube following with videos covering nutrition plans, fitness instruction, stress relieving tips, and other content centered on healthy habits.

Also sharing her expertise on vitamin C is Dr. Lucie Kotlářová, PharmD, Director of InPharmClinc, a clinic focused on adjuvant oncologic treatment in the Czech Republic. Dr. Kotlářová will be available for a discussion of best practices for using liposomal vitamin C as an adjunct to intravenous ascorbic acid. Presentations will be on Friday, December 13 (11:30am) and Saturday, December 14 (11:30am and 3:45pm) at the Sovereign Laboratories booth.

Visit the Sovereign Laboratories booth (#3078) for more information or to try a sample of PRO Colostrum-LD®. Learn more or register online at http://www.ColostrumTherapy.com.

About Sovereign Laboratories:

Sovereign Laboratories is dedicated to developing natural products that provide the most efficacious solutions for optimal health, vitality, and aesthetics. Company founder Douglas Wyatt is the world’s leading authority on bovine colostrum and is credited with establishing the gold standard in colostrum supplements. Sovereign Laboratories’ signature product Colostrum-LD® is clinically proven to heal the G.I. lining; prevent infection and inflammation of the bowel; and increase bowel surface area for better nutritional absorption. Colostrum-LD® is considered the premier foundational supplement for optimal gut and immune health, and it was designed for successful aging no matter where one is on the spectrum of life.

Share article on social media or email:

Wild Harvested meat and fish positively contribute to food security and human health.

We believe this initiative will have a lasting influence on the narrative surrounding the undeniable benefits of recreational hunting and fishing – Dan Cabela

ST. JOHN’S, Newfoundland (PRWEB)
December 09, 2019

Conservation Visions is announcing a new partnership with the Cabela Family Foundation, the philanthropic legacy of Dick and Mary Cabela, in support of the Wild Harvest Initiative®, the first attempt to synthesize and evaluate the combined economic, conservation and social benefits of recreational wild animal harvests in North American society. This program represents a forward-looking approach that works within existing social trends to build new alliances for wildlife conservation, to expand the value portfolios for wildlife and wild lands and waters, and to normalize hunting and fishing.

The Initiative will address many questions such as: How do hunting and fishing contribute to the food security of American and Canadian citizens? How much would it cost to replace this food, not just in dollars and cents, but environmentally, if everyone stopped hunting and fishing? By exploring sustainable use of wildlife in the contexts of food security, human health and fitness, wildlife and habitat conservation, animal health and welfare, ecological and environmental concerns, and economic prosperity, the program will explore the wider benefits of wildlife and wild animal harvest to the public.

“The Wild Harvest Initiative® derives its energy from society’s culture of change, working with the tides instead of against them, so to speak, to achieve optimal results” says Shane Mahoney, Conservation Visions’ CEO and originator of the Wild Harvest Initiative®. “We are delighted to welcome the Cabela Family Foundation, a leader in the promotion of outdoor recreation, conservation, and charitable works, to our Partnership Alliance. Together, we look forward to making a positive difference in the lives of others, while we work to conserve wildlife.”

“The Cabela Family Foundation is pleased to announce our partnership with Wild Harvest Initiative® as they identify and share the physical, environmental, emotional, and economic impacts of the sustainable harvest of wildlife,” says Dan Cabela. “We believe this initiative will have a lasting influence on the narrative surrounding the undeniable benefits of recreational hunting and fishing.”

Share article on social media or email: